RIVAL - Valuation & Licensing Software for Biopharma
Rival is a value management software platform that allows you to model the value and licensing terms of your pipeline assets.
Trusted by leading
pharma & biotech companies
Find out how we can serve your needs
What can you achieve using RIVAL?
With RIVAL you will be able to communicate the value of your efforts to all stakeholders, manage risks and turn your R&D work into a successful financial outcome.
Quantify the value of your pipeline & monitor the development over time
Perform sensitivity analysis on key value drivers (time, risk, free cash flow)
Model the value of existing or future licensing contracts
Compare your valuation with similar private or public companies
Get access to curated partners or investors
licensing deal terms
How the platform works
Asset Value Modelling
The software allows you to model the value of your asset per indication and geography and provides guidance on the different input parameters and bench-marking data. This output is visualized in clear and insightful graphics and allows for sensitivity analysis of key value drivers.
Portfolio Value Management
View the status of multiple projects on a single timeline in a snapshot and grow your ROI. Cross-portfolio visibility saves valuable time, increases decision-making accuracy, and keeps everyone aligned.
Licensing Deal Simulation
The Licensing Deal Module allows for licensing deal terms simulation and optimization. The clear visualizations provide powerful insights in the value split between parties, breakdown of the allocated economics and bench-marking of the deal terms
Discover how RIVAL will support your funding efforts
Why choose RIVAL?
An easy-to-access platform that puts it all at your fingertips
RIVAL is the premier resource for comprehensive pharma and biotech valuations, sensitivity analysis, portfolio management, license deal modelling, generating insights designed to empower your best business decisions
Avance has served over 450 clients and supported USD 10B+ deal value
Based on the Book written by Avance team “Valuation in Life Sciences”. That is the textbook used by INSEAD, Wharton and Harvard Business School
Trained more than 2,500 life sciences professionals on 4 continents through our valuation courses
We work with a pool of highly experienced executives from top-tier companies in the industry (e.g. Roche/Novartis/BMS/Novo Nordisk etc.)
Enter you details and book a free consultation with our team